Insulin long-acting (HM 12460A) - Hanmi Pharmaceutical

Drug Profile

Insulin long-acting (HM 12460A) - Hanmi Pharmaceutical

Alternative Names: HM 12460A; HM 12460B; LAPS-Insulin - Hanmi Pharmaceutical; LAPSInsulin; Ultra-Long Acting Insulin - Hanmi Pharmaceutical

Latest Information Update: 11 May 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Nov 2015 Insulin long-acting licensed to Sanofi worldwide for the treatment of Type-1 and type-2 diabetes mellitus
  • 06 Feb 2014 Hanmi Pharmaceutical completes enrolment in its phase I trial for Type-1 and type-2 diabetes mellitus in USA (NCT01724814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top